Click' Login' then 'Don't have an Account ' and join $$Lounge for free

Lexaria Corp CSE:LXX OTC:LXRP

More
1 week 2 days ago #121260 by RonS
RonS replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Among World’s Biggest Holders of Cannabis Patents

NEW YORK, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector,” featuring Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP).

To hear the CannabisNewsAudio version, visit: cnw.fm/99vVo

To read the full editorial, visit: cnw.fm/z0TDt

Outside of China, Lexaria is one of the world’s biggest holders of cannabis patents with eight patents already granted. The company currently holds four patents in the United States and four in Australia, covering aspects of its work to make beneficial drugs more palatable and effective. In addition, the company has further patent applications in process in more than 40 countries as part of a concerted strategy to expand its patent portfolio. This is made possible by the focused, tangible research and development being carried out by the company and is ultimately driven by the need to develop and control intangible assets.

Lexaria has disclosed it expects four more patents to be granted in 2018, bringing its total to twelve. Of note, all twelve of these are within a single patent family — and Lexaria expects patent success across all nine families of its current applications. Indeed the company recently revealed that it has seven more patent families in the works. Lexaria’s goal is to have some 200 patents pending or granted which, if achieved, could turn the organization into an IP behemoth in the global cannabis industry.

Please Log in or Create an account to join the conversation.

  • lynnsa10
  • lynnsa10's Avatar
  • Away
  • Elite Member
  • Elite Member
More
1 week 6 days ago #121214 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
SEATTLE, Oct. 03, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. (CSE: LXX) (LXX: CN) (CNSX: LXX) (OTCQX: LXRP). The company has developed an innovative drug delivery platform that increases intestinal absorption rates, rapidly delivers active ingredients to the bloodstream, and provides taste-masking benefits.

The cannabis industry is heating up with the legalization of medical and recreational cannabis across Canada and a growing number of states. While cannabis flower has been the early focus, cannabinoid-infused edibles and concentrates represent the fastest growing segments of the $100+ billion industry.

Absorption is one of the most important differentiators for both medical and recreational cannabis products. Medical cannabis patients want to receive a standardized dose and consistent effect each time, while recreational consumers want to experience a high as quickly as possible.

“We are focused on making ingestible or edible bioactive substances taste better, smell better, act faster and enhance potency,” says Lexaria President John Docherty, a trained pharmacologist and toxicologist, who is also the former president and chief operation officer of Helix BioPharma Corp.

Internal R&D vs. Outsourcing

Many cannabis companies plan to launch cannabis-infused products over the coming year. In fact, the alcohol industry has been so concerned about the potential for these products that giants like Constellation Brands Inc. and Molson Coors Brewing Co. have made significant investments.

With the race to develop alternative cannabis products, many cannabis companies have a choice between developing internal delivery platforms or partnering with experts to develop top-performing products. Internal develop involves a high cost and potentially lengthy delays but provides flexibility, while partnerships can provide speed to market and a known solution at a predetermined cost.

Lexaria Biosciences’ innovative drug delivery platform enables cannabis absorption in just 10 to 20 minutes compared to the 60 to 120 minutes for many cannabis edibles on the shelves today. The technology also represents an alternative to sugars and chemicals that are often used to mask flavors. Lexaria was one of the first to offer these solutions to the cannabis industry.

The company has already licensed its products to numerous cannabis companies. For example, the company’s customers include the maker of the 1906 brand of cannabis-infused chocolates in Colorado, a Canadian-based developer of cannabis wines and beers, and a new Canadian company focused on cannabis-infused edibles.

Clinically Proven Advantages

Lexaria’s DehydraTECH platform has shown tremendous promise in several different clinical studies. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the earthy taste of cannabis and delivers it more effectively.

Earlier this year, the company released the results of a randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD—a proprietary DehydraTECH powered CBD hemp oil capsule—showing 317% greater absorption at the 30 minute mark and higher blood concentration. Lexaria is one of very few companies anywhere in the world to have completed human clinical studies related to cannabinoids and have proven that its technology is effective.

The company conducted similar studies of DehydraTECH’s potential with other active ingredients, such as nicotine. In an in-vivo animal study, researchers delivered DehydraTECH powered nicotine in an edible form into blood plasma in just minutes after dosing with 90.2 percent greater delivery than control after just 10 minutes. Lexaria is one of the only companies in the world with technology proven effective in both the nicotine and cannabis industries.

Looking Ahead

Lexaria’s growing portfolio of more than 50 patents has expanded its drug delivery platform well beyond cannabis, including vitamins, NSAIDs, nicotine, and other molecules. Management plans to develop the patent portfolio into 150 to 200 patent applications around the world within two years.

Investors interested in capitalizing on the burgeoning cannabis industry along with additional potential across other multi-billion dollar markets may want to take a closer look at the company ahead of further partnerships and announcements.

For more information, visit the company’s website or download their investor presentation.

Please follow the link to read the full article: www.cannabisfn.com/race-speed-effects-cannabis/

Please Log in or Create an account to join the conversation.

More
2 weeks 1 day ago #121193 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Quite a correction in Pot stocks today, it had to happen

Please Log in or Create an account to join the conversation.

  • lynnsa10
  • lynnsa10's Avatar
  • Away
  • Elite Member
  • Elite Member
More
3 weeks 16 hours ago #121157 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Sector is very frothy, let some of that roll into LXX

Please Log in or Create an account to join the conversation.

More
3 weeks 6 days ago #121133 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP

Please Log in or Create an account to join the conversation.

More
2 months 2 weeks ago #120877 by Hoss
Hoss replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Very Positive news today

Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

KELOWNA, BC / ACCESSWIRE / August 1, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to report significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBDTM - a proprietary, DehydraTECH™ powered, cannabidiol ("CBD") fortified hemp oil capsule developed by Lexaria. The degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers were studied.

Key bioavailability data highlights from the study comparing the 90 mg dose of Lexaria's TurboCBD™ to a 90 mg dose of a positive control formulation without Lexaria's DehydraTECH™ technology were as follows:

30 Minutes: CBD delivered from Lexaria's TurboCBDTM capsules was absorbed much more effectively than from the positive control, delivering 317% more CBD to blood at the 30-minute mark of the study (i.e., 18.4 ng/mL compared to only 4.4 ng/mL on average respectively [95% CI; p=0.051]);
60 Minutes: The TurboCBDTM capsules went on to deliver more CBD to the blood at the 60-minute mark (i.e., 38.8 ng/mL) than the positive control capsules were able to reach at any time during the 6-hour study, further demonstrating the exceptional rapidity of action and effectiveness of the TurboCBD™ capsules;
90 Minutes: The TurboCBDTM capsules further went on to deliver significantly more CBD to the blood (86% more) than the positive control capsules at the 90-minute mark (i.e., 53.0 ng/mL compared to only 28.4 ng/mL respectively [95% CI; p=0.034]);
Through to Study Completion: Lexaria's TurboCBDTM capsules continued to deliver more CBD to blood than the positive control capsules at each subsequent time point in the study through to the 6-hour mark when the study was completed.

These results corroborate and confirm earlier in vitro and in vivo studies that have evaluated Lexaria's DehydraTECHTM technology and have consistently measured higher levels of drug delivery much more quickly than positive controls with matching CBD concentrations. Although this study evaluated absorption only of CBD and its metabolites, Lexaria believes nearly identical bioavailability enhancement results would be achieved if the cannabinoid studied was THC instead of CBD.

Please Log in or Create an account to join the conversation.

More
3 months 4 weeks ago #120757 by RonS
RonS replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Yes, stock is on the verge of a breakout

Please Log in or Create an account to join the conversation.

More
4 months 3 days ago #120742 by DearJohn
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
I am holding, this is going to break out to the upside. Can feel it, Pot is where all the action has been

Please Log in or Create an account to join the conversation.

More
4 months 3 days ago #120728 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
stock still trying to make that break out. I am cheering

Please Log in or Create an account to join the conversation.

More
4 months 1 week ago #120686 by alexgreat
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
stock is breaking out, looks like we are headed to old $3.00 highs

Please Log in or Create an account to join the conversation.

More
4 months 2 weeks ago #120662 by alexgreat
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
CFN Media's Exclusive Interview With Lexaria Bioscience CEO Chris Bunka

SEATTLE, May 31, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Lexaria Bioscience Corp. (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQX:LXRP). The company is paving the road in terms of cannabinoid delivery research and development. Their patented DehydraTECH™ technology allows for the oral consumption of cannabinoids without the typical scent and flavor, while also avoiding first-pass liver metabolism. Nuka Enterprises LLC, one of the largest edible manufacturers in the world, recently signed a 10-year agreement with Lexaria in order to continue bringing delicious and effective 1906 chocolates to consumers across the globe.

CFN Media spoke with Lexaria CEO Chris Bunka at the recent MJBizNEXT Conference in New Orleans to learn more about the firm’s innovation and their plans to dramatically change the way people think about cannabis.

CFN: How does your DehydraTECH™ delivery method work?

Chris Bunka: We believe that infused foods should taste more like food and less like marijuana. Our consumers find their coffee tastes a bit more like coffee and less like cannabis, and additionally notice that the cannabinoids take effect faster, and they feel a different type of effect than the typical edible. For medical patients who medicate often, that difference means a lot.

Our tech allows cannabinoids to avoid first pass liver metabolism, and that's why we have some dramatic biochemical differences. We take a cannabinoid and we kind of “glue” it to oleic acid, which is a sub-component of sunflower oil or olive oil; both long chain fatty acids.

That “gluing” is really important, and sunflower oil is a really good choice because it has a neutral taste. If you tried olive oil, you'll taste plant, it tastes different. So, when we “glue” the THC or the CBD or the terpenes to the oleic acid, you get that neutral flavor, and it's pretty dramatic in most things. We put it in coffee, tea, water, white wine, beer, protein bars, cookies, chocolates, candies, gummies; we put it into so many things. Basically, about 99 percent of the strong flavor is gone, and you don't have to add any sugar, and you don't have to add any chemicals.

When you swallow food, it goes into your stomach. Whatever doesn't get absorbed obviously gets excreted as waste, but as it passes through the intestine, there's all these opportunities to get absorbed across the intestinal wall. Well, the intestinal wall is not just a filter. It's not just this physical barrier. It's actually a very highly communicative, two way, sensing organ. There's sensing apparatus all over it, and those sensory cells are looking for what is it that's here. “Is it a fat? What kind of fat? Is it a protein? Is it sugar? What kind of sugar?”

Depending on all sorts of different stuff, which one of those receptors are being triggered, different signals get sent to your pancreas and different biomes are created to help pull those nutrients across the intestinal wall. Your body is actually actively trying to pull those nutrients in. Well, oleic acid is like the wonder molecule as far as your intestine is concerned. It's one of the only things you can swallow that does not get passed through the intestinal wall and then delivered to the hepatic vein that goes to the liver for first pass liver absorption.

CFN: Tell us about your intellectual property?

CB: Our patent portfolio is super strong. Last December, we received our first patent from the U.S. Patent Office on nicotine and the ibuprofen and aspirin delivery as well as the cannabinoids. We're in the active investigation phase in the EU, Canada, China, Japan, and India right now, so we'll probably have additional progress there soon. Our IP lawyer has joined our advisory board because he's really fascinated with what we're doing, and he has a PhD in neuroscience, as well as being a patent attorney.

We're filing new patent applications all the time. So, in the industry, I know that GW certainly has more patents and patent applications than we do, and I know that Canopy up in Canada is pretty much neck and neck with us. They're in the 30-40 patent application range, and so are we. Maybe we're a little ahead by numbers, but I'm almost certain that Canopy, for example, has no granted patents, and I know that GW only has a few, and we are kind of neck and neck with them also. We are right at the leading edge in the world for patent applications and patent granting, and IP in the cannabis sector.

CFN: What types of exciting discoveries have you been making in your research?

CB: We conducted a study recently on rats, using nicotine as an active ingredient. Blood tests showed we are getting an average of 50 percent more nicotine into the rats' blood compared to rats in the control group. We said okay, well, that's good. So, if I had 10 milligrams of THC, it'll have the effect of 15 compared to not using our tech. We also took kidney, liver and brain tissue samples, and found in the brain we had 560 percent more nicotine with our tech than without. That is a profound discovery because frankly, we don't know exactly how we did it. There was 50 percent more level in the blood plasma and so you would naturally think, “Okay, there's 50 percent more available to penetrate to receptors anywhere”, but instead it increased 11-fold: 50 percent to 550.

We already knew that our tech crosses the intestinal wall way more effectively but based on these results, we're wondering if affects blood-brain barrier transmission as well. If it does, this has the potential to have profound ramifications for pharmaceuticals and biotech, and not just cannabis. Here is research that is being done, all originating out of the cannabis industry, for the cannabis industry, that could have profound public health consequences for applications from cancer, brain tumors, the ability to be able to deliver to the brain substances that right now can't get across that barrier.

That's massive potential but it is early, early, early days, and we've done one study, and it's on rats, it's not humans; so there's a lot of area we still need to grow our knowledge. Still, it's a profoundly unusual and unexpected result, and we've talked to a number of leading PhD researchers around the world in the three weeks since we've published that, and none of them can explain it. We're going to repeat the study and do a larger population of animals. We only had 12 rats in that study. In the next one, we were thinking of doing 30, or 40, or 50. That would give you more robust data and additional opportunities. If it repeats, I can't tell you how big this is to us.

CFN: Why should potential investors consider Lexaria?

CB: Unlike some companies, we really do actually respect our shareholders. I don't go for this new modern idea of issuing hundreds and hundreds of millions of shares because there is a big cost to issue 100 million shares which will raise a lot of money in the process: and yes it can help you build your business and yes it can help you to preserve your jobs - it can do all those things. That's all really, really good: but you've completely skewered your investors because you've issued so many shares. How much additional value are you going to have to create to justify that market cap? If you look at us, our share count has probably grown among the least on the continent in the last three to four years compared to other companies in our sector. We're at about 71 million shares outstanding today. That's still really low compared to most of the others.

Unlike some of these other companies that need tens of millions of dollars to operate and grow before they hit cash-flow positive or profitability, our burn rate is super, super low - so a couple million dollars goes a long way with us, and our cash-flows are increasing, because we're a licensing and R&D company. One of the biggest considerations of all the companies that you can think of that are public in the cannabis space - I don't think there's another one that comes remotely close to us in this way - is to be able to match the applicability of our business model outside of cannabis. Our valuation has gone up by close to 2000 percent in the last couple of years because our tech applies to several different sectors.

One of the main things I want people to realize is: this is for real. This is not a game to the management of Lexaria. None of us are interested in some quick market appreciation in order to dump a million bucks worth of stock. I started buying stock in this company in 2005, and I have never sold a share. In 2014-15, I bought about another 6 million shares out of the market, just like anyone else can, and I've never sold one of those shares, either. They're all sitting in my accounts. I know it's so corny, but we are actually interested in changing the world. We think we can slow down disease, we think we can save lives, we think we can make cannabis more acceptable for the general population and take the stink factor out, and that's all positive stuff.

We ARE going to make the world a better place and our accomplishments so far are nothing compared to what we have planned.

Please visit the company website: www.lexariabioscience.com

Please follow the link to read the full article:

www.cannabisfn.com/cfn-medias-exclusive-...nce-ceo-chris-bunka/

About CFN Media

Please Log in or Create an account to join the conversation.

  • lynnsa10
  • lynnsa10's Avatar
  • Away
  • Elite Member
  • Elite Member
More
5 months 3 weeks ago #120587 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Great news first licensing deal in California, the largest Pot market

Kelowna, British Columbia / TheNewswire / April 25, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with GP Holdings LLC. ("GP") whereby Lexaria is providing its patented DehydraTEC H(tm) technology to empower next-generation performance in high absorption, fast acting cannabis infused beverages to be developed and sold in California.

GP is establishing its operation as the leading THC beverage contract manufacturer in the state of California and expects the commencement of operations from its new state-of-the-art bottling facility within the next two quarters. Lexaria and GP have been collaborating for months to develop the highest performing cannabis beverages available anywhere, with nearly zero unwanted cannabis odor or flavor, and complete clarity and transparency of even sparkling beverages. More info about GP can be found at www.growpacker.com

GP has acquired 5-year semi-exclusive rights to use Lexaria's DehydraTEC H(tm) technology for beverage applications within California for an undisclosed sum and a royalty on revenue generated on products sold utilizing DehydraTEC H(tm) . In addition, GP also intends to develop topical skin products using the technology and has also acquired matching rights for this application.

The California cannabis-bev erage market is expected to be one of the largest edible product segments, and this agreement continues Lexaria's progress of building an international ecosystem empowering licensed producers of all sizes with the ability to create best-of-class sector leaders. Under the terms of the semi-exclusive Agreement, Lexaria can offer other licensee partners the option of utilizing GP's formulation and manufacturing expertise to produce cannabis infused, DehydraTEC H(tm) -powered beverages and topicals throughout the state of California.

"The use of DehydraTEC H(tm) triggers a race to the top in the California THC beverage and topicals market through this 5-year license agreement," said Chief Executive Officer Chris Bunka. "This is another long-term strategic relationship that will give consumers the faster acting and highly potent products they deserve, and class leading flavor profiles for the beverage segment in particular."

Please Log in or Create an account to join the conversation.

Time to create page: 0.864 seconds

Login Form